The White House sees no job losses from AI, yet major tech and pharma companies have announced more than 40 rounds of layoffs this year, citing efficiency and AI as drivers.
Back
Tech layoffs surge past 40 rounds despite White House AI claims
A senior White House official stated there is “no sign in the data” that artificial intelligence is costing jobs, a comment that stands in sharp contrast to a wave of AI-related job cuts announced by major technology and pharmaceutical companies in 2026.
"There's no sign in the data that it's costing anybody their job," National Economic Council Director Kevin Hassett said on May 11. His remarks come as corporations, including Amazon, Meta, and Oracle, have publicly cited AI as a factor in workforce reductions aimed at improving operational efficiency and redirecting investment.
The data on job losses paints a different picture. More than 40 rounds of layoffs were announced in the first four months of the year, according to one industry tracker. This trend follows a turbulent 2025 where job losses rose 16% year-over-year amid market pressures and strategic shifts by large corporations.
This conflict between official statements and corporate action highlights a growing uncertainty in the labor market. While some analysts predicted a slowdown in job cuts for 2026, the current pace suggests that corporate restructuring, often with an eye toward AI integration, continues to be a significant factor for investors and employees alike.
A tale of two trends
The reasons behind the recent layoffs are complex, extending beyond a simple AI narrative. Many cuts stem from familiar industry pressures, including investigational drug failures, strategic reprioritizations, and broad efforts to streamline operations.
Vistagen, for instance, reduced its workforce by about 20% to conserve capital after a Phase 3 trial failure for its lead drug candidate. Similarly, oncology biotech Replimune cut 224 jobs following a surprising FDA rejection of its melanoma drug, RP1. These cases show that traditional business risks remain a primary driver of layoffs.
However, other reductions are explicitly tied to larger reorganization plans where AI plays a role. Takeda Pharmaceutical is in the midst of a billion-dollar-plus restructuring that will eliminate over 600 positions, with the stated goal of redirecting savings into R&D and new drug launches—areas where AI is increasingly applied.
Beyond the tech sector
The trend of workforce reductions in the name of efficiency is not confined to the tech industry. In early May, BioNTech announced a major restructuring, including the elimination of an estimated 1,860 jobs, as it pivots from its COVID-19 vaccine to oncology research.
Even pharmaceutical giant Merck & Co. is trimming its global workforce by 8% as it prepares for the patent expiration of its blockbuster drug Keytruda. A recent round of 150 job cuts at its Durham, North Carolina, plant was a direct response to slowing demand for its Gardasil vaccine, leading the company to scale back manufacturing.
While many of these layoffs are driven by market-specific pressures, the specter of AI looms over the future of employment. For now, some industry observers contend it is too soon to measure the full impact of artificial intelligence on jobs. Still, for companies like Amazon, Meta, and Merck, the push for efficiency and cost-savings—often enabled by AI—is a reality that is already reshaping their workforce.
This article is for informational purposes only and does not constitute investment advice.
[1] Hassett says AI isn't costing anybody their job right now — but tech layoffs keep coming[2] Biotech layoffs are easing, but is the worst over?[3] Analysts warn AI layoffs fail to boost corporate returns[4] S&P 500 and Nasdaq hit records on jobs boost[5] Graduates face tough job market as AI reshapes careers
